| "Cillobacterium cellulosolvens" Bryant et al. 1958| [Eubacterium] cellulosolvens| ATCC 43171| Cillobacterium cellulosolvens| Eubacterium cellulosolvens| Eubacterium cellulosolvens (Bryant et al. 1958) Holdeman and Moore 1972 (Approved Lists 1980) emend. van Gylswyk and van der Toorn 1986| JCM 9499| strain Bryant B348
Gut microbiota: Eubacterium species, including Eubacterium cellulosolvens, are prevalent components of the gut microbiota. They play important roles in maintaining gut health by contributing to the fermentation of dietary fibers, the production of short-chain fatty acids (SCFAs), and the regulation of intestinal homeostasis. SCFAs produced by Eubacterium species, such as acetate, propionate, and butyrate, serve as energy sources for colonocytes and play key roles in immune modulation and gut barrier function.
Metabolic health: Some studies have suggested associations between the abundance of Eubacterium species in the gut microbiota and metabolic health outcomes, such as obesity, type 2 diabetes, and metabolic syndrome. Eubacterium species are involved in the metabolism of dietary components, including complex carbohydrates and host-derived mucins, and may influence energy balance and glucose metabolism. Dysbiosis of the gut microbiota, characterized by changes in the abundance or composition of Eubacterium species, has been implicated in metabolic disorders.
Inflammatory bowel disease (IBD): Dysbiosis of the gut microbiota, including alterations in the abundance of Eubacterium species, has been associated with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. While some Eubacterium species have been reported to decrease in abundance in individuals with IBD, others may increase in abundance or exhibit shifts in their functional properties. The exact roles of Eubacterium species, including Eubacterium cellulosolvens, in the pathogenesis of IBD are still being elucidated.
Immune modulation: Eubacterium species interact with the host immune system through various mechanisms, including the production of immunomodulatory molecules and the regulation of inflammatory responses. Some Eubacterium species have been reported to exert anti-inflammatory effects and may play protective roles in the gut mucosa. However, the specific immunomodulatory properties of Eubacterium cellulosolvens are not well characterized.
Butyrate production: Eubacterium species, including Eubacterium cellulosolvens, are known butyrate producers. Butyrate is a SCFA that serves as a preferred energy source for colonocytes and has been implicated in maintaining gut barrier integrity, reducing inflammation, and protecting against colorectal cancer. Therefore, Eubacterium cellulosolvens may contribute to these beneficial effects through its butyrate-producing capacity.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 0.93 | 10 | 1770 | 0 | 1032 | 269.7 | 160 | 389.1 | 0 | 380 | 0 %ile | 100 %ile | ||
thryve | 93.05 | 19 | 3222 | 112 | 3370 | 0 | 7288 | 1975.7 | 942 | 2710.2 | 0 | 4166 | 10.6 %ile | 92 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
BiomeSightRdp | 29.032 % | 0.029 % | 0.016 % | 9.0 | 31 |
CosmosId | 28.125 % | 0.006 % | 0.004 % | 9.0 | 32 |
custom | 11.475 % | 0.052 % | 0.086 % | 7.0 | 61 |
es-xenogene | 17.241 % | 0.039 % | 0.015 % | 5.0 | 29 |
Thryve | 94.249 % | 0.201 % | 0.282 % | 1311.0 | 1391 |
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.